Ex Parte LI et al - Page 5



              Appeal No. 2003-1020                                                                  Page 5                 
              Application No. 08/859,051                                                                                   
              skilled in the art would reasonably expect the topically applied liposomal composition of                    
              Bonte and R[ö]ssling would enter the hair follicles from the teachings of [du] Plessis”                      
              (Answer, page 5).                                                                                            
                     Nevertheless, the examiner does not identify anything in Rössling or Bonte (or                        
              du Plessis) that would indicate that there is any disadvantage associated with liposomal                     
              preparations containing some unencapsulated agent.  Indeed, Bonte specifically                               
              teaches that “it is not necessary that the whole of the active principle be incorporated or                  
              encapsulated in order to obtain the desired effect” (Bonte, column 7, lines 40-44).                          
              Mezei, like Bonte and Rössling, demonstrates that encapsulating an active agent in                           
              liposomes results in higher local potency and fewer systemic effects, but does not                           
              comment on the effect, if any, of removing all unencapsulted active agent from the                           
              liposomal preparation.  In any case, claims 116-121, at least, require selective                             
              deposition “to the cells of the hair follicle and to the hair shaft itself” rather than “the                 
              dermis or the circulation,” but Mezei noted substantial deposition of liposomally-                           
              encapsulated triamcinolone in the dermis and epidermis.  Finally, we cannot agree with                       
              the examiner’s interpretation of du Plessis - there is nothing in the reference to indicate                  
              that liposome-encapsulated active agent preferentially enters the hair follicles; rather,                    
              du Plessis seems to indicate that the “follicular route” or “follicular pathway” is an                       
              effective conduit for “drug transport into strata below and beyond the stratum corneum,”                     
              i.e., transport into dermal layers below the skin’s surface (page 263).                                      
                     Clearly, the examiner has established that individual parts of the claimed                            
              invention were known in the prior art.  However, as explained in In re Kotzab, 217 F.3d                      
              1365, 1369-70, 55 USPQ2d 1313, 1316 (Fed. Cir. 2000) (citations omitted):                                    
                     A critical step in analyzing the patentability of claims pursuant to section                          
                     103(a) is casting the mind back to the time of invention, to consider the                             
                     thinking of one of ordinary skill in the art, guided only by the prior art                            


Page:  Previous  1  2  3  4  5  6  7  8  Next 

Last modified: November 3, 2007